EspeRare et Genetic Alliance développent GaugeRx
10juin
GaugeRx, un nouvel outil digital d'évaluation est en développement pour accélérer le développement de médicaments pour les maladies rares.
WASHINGTON, DC – June 10, 2013 – The EspeRare Foundation of Geneva, Switzerland and Genetic Alliance of Washington, DC announced a collaboration to streamline the process of translating research into health outcomes by strengthening the decision-making for drug development. The collaboration will result in a dynamic, web-based analytics and assessment tool that integrates and translates vast amount of knowledge about human health and disease to support drug (re)positioning and development decision-making for a broad range of healthcare stakeholders, from pharmaceutical companies to advocacy groups.